Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767060 | 0.86 | CA2 (0.61) | CA2MTNR1ACHRNB2CHRNA4MAPT | |
| SCHEMBL3817884 | 0.85 | CA2 (0.70) | CA2MTNR1ACHRNB2CHRNA4MAPT | |
| SCHEMBL1928101 | 0.83 | CHRNB2 (0.64) | CA2CHRNB2CHRNA4MAPTCYP1A2 | |
| SCHEMBL1927790 | 0.83 | CA2 (0.57) | CA2CHRNB2CHRNA4MAPTCYP1A2 | |
| SCHEMBL20015583 | 0.81 | HDAC6 (0.64) | CA2F10MEN1KMT2AHDAC2 | |
| SCHEMBL6824957 | 0.80 | CHRNB2 (0.67) | CA2MTNR1ACHRNB2CHRNA4MAPT | |
| SCHEMBL1386337 | 0.79 | MTNR1A (0.76) | CA2MTNR1ACHRNB2CHRNA4MAPT | |
| SCHEMBL28348828 | 0.78 | HPGD (0.74) | MAPTPKM | |
| SCHEMBL6570852 | 0.78 | CA2 (0.69) | CA2CHRNB2CHRNA4MAPTMEN1 | |
| SCHEMBL1927457 | 0.78 | CSNK1D (0.55) | CA2CHRNB2CHRNA4MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | CA2 1905/4885MTNR1A 2339/4885CHRNB2 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.